Drugs / CC-101
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07709845 | Jan 2027 → Jan 2029 expected | ischemic stroke | Clarion Cells, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CC-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07709845 ↗ |
| Known as | NR1 | “CC-101 (f/k/a NR1) is an investigational allogeneic neural stem cell therapy being developed to support endogenous repair and regenerative mechanisms within the brain following...” NCT07709845 ↗ |
| Modality | Cell therapy | “allogeneic neural stem cell therapy” NCT07709845 ↗ |
| Route | Other | “administered stereotactically via intracerebral injection immediately adjacent to the prior stroke lesion” NCT07709845 ↗ |